653
edits
Difference between revisions of "Invasive breast cancer"
Jump to navigation
Jump to search
→Breast IHC
| Line 156: | Line 156: | ||
*Overview | *Overview | ||
**A category of breast carcinomas defined by gene expression profiling | **A category of breast carcinomas defined by gene expression profiling | ||
**''Not used'' in clinical practice | |||
**Somewhere between 15-30% of breast carcinomas. | **Somewhere between 15-30% of breast carcinomas. | ||
**Can be identified by immunohistochemistry - basal markers (CK14, p63, calponin, SMA) | **Can be roughly be identified by immunohistochemistry - basal markers (CK14, p63, calponin, SMA) | ||
**Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells | **Not derived from myoepithelial cells, merely express a phenotype more in keeping with basal cells than ductal cells | ||
**Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents | **Most triple negative (ER, PgR, Her-2); therefore cannot be treated with the usual therapeutic agents | ||
| Line 200: | Line 201: | ||
**A category of breast carcinomas defined by immunohistochemical/FISH expression of ER, PR and HER2. | **A category of breast carcinomas defined by immunohistochemical/FISH expression of ER, PR and HER2. | ||
**''Important to identify'' in clinical practice. | |||
**About 15% of breast carcinomas. | **About 15% of breast carcinomas. | ||
**Important group due to a lack of tailored therapies for this group | **Important group due to a lack of tailored therapies for this group | ||